Compare Aurora Cannabis Inc (ACB) vs Byrna Technologies Inc (BYRN) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

BYRN trades at $7.08, up 1.58% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $16.75. The company reported Q4 2025 EPS beat but a Q1 2026 miss, with revenue of $118.12M in 2025 and a net income margin of 7.3%. Recent news highlights strategic marketing expansions and upcoming Q2 2026 earnings.

Outlook is cautiously optimistic given strong analyst buy ratings (71.4%) and a high price target upside, though risks include negative cash flow, ongoing legal investigations, and margin pressure from retail channel shifts. Earnings growth and successful execution of new initiatives are critical for sustained upside.